Literature DB >> 12608452

Systemic effects of chronic obstructive pulmonary disease.

A G N Agustí1, A Noguera, J Sauleda, E Sala, J Pons, X Busquets.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by an inappropriate/excessive inflammatory response of the lungs to respiratory pollutants, mainly tobacco smoking. Recently, besides the typical pulmonary pathology of COPD (i.e. chronic bronchitis and emphysema), several effects occurring outside the lungs have been described, the so-called systemic effects of COPD. These effects are clinically relevant because they modify and can help in the classification and management of the disease. The present review discusses the following systemic effects of chronic obstructive pulmonary disease: 1) systemic inflammation; 2) nutritional abnormalities and weight loss; 3) skeletal muscle dysfunction; and 4) other potential systemic effects. For each of these, the potential mechanisms and clinical implications are discussed and areas requiring further research are highlighted.

Entities:  

Mesh:

Year:  2003        PMID: 12608452     DOI: 10.1183/09031936.03.00405703

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  196 in total

1.  Preclinical vascular disease identifies smokers at risk for COPD.

Authors:  James D Crapo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-04       Impact factor: 11.205

2.  Long lasting effects of smoking: breast cancer survivors' inflammatory responses to acute stress differ by smoking history.

Authors:  Jeanette M Bennett; Ronald Glaser; Rebecca R Andridge; Juan Peng; William B Malarkey; Janice K Kiecolt-Glaser
Journal:  Psychoneuroendocrinology       Date:  2012-06-21       Impact factor: 4.905

Review 3.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

Review 4.  COPD exacerbations.5: management.

Authors:  R Rodríguez-Roisin
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

Review 5.  Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Authors:  Matthew C Miles; James F Donohue; Jill A Ohar
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

Review 6.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 8.  Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.

Authors:  Vanessa M McDonald; Isabel Higgins; Peter G Gibson
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

9.  Double deficiency of tetraspanins CD9 and CD81 alters cell motility and protease production of macrophages and causes chronic obstructive pulmonary disease-like phenotype in mice.

Authors:  Yoshito Takeda; Ping He; Isao Tachibana; Bo Zhou; Kenji Miyado; Hideshi Kaneko; Mayumi Suzuki; Seigo Minami; Takeo Iwasaki; Sho Goya; Takashi Kijima; Toru Kumagai; Mitsuhiro Yoshida; Tadashi Osaki; Toshihisa Komori; Eisuke Mekada; Ichiro Kawase
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

10.  Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke.

Authors:  Saravanan Rajendrasozhan; Jae-Woong Hwang; Hongwei Yao; Nandini Kishore; Irfan Rahman
Journal:  Pulm Pharmacol Ther       Date:  2010-01-18       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.